88. 慢性血栓塞栓性肺高血圧症 Chronic thromboembolic pulmonary hypertension Clinical trials / Disease details
臨床試験数 : 157 / 薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54
Showing 1 to 10 of 16 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-001642-17-IT (EUCTR) | 06/08/2014 | 12/09/2013 | An extension study of a drug to treat Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) An extension study of a drug to treat Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEP ... | An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentanin su ... | Subjects with inoperable Chronic Thromboembolic PulmonaryHypertension (CTEPH) MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Subjects with inoperable Chronic Thromboembolic PulmonaryHypertension (CTEPH) MedDRA version: 17.0;L ... | Trade Name: Volibris Product Name: Ambrisentan Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN Other descriptive name: Ambrisentan Trade Name: Volibris Product Name: Ambrisentan Product Code: GSK1325760 INN or Proposed INN: AMBRISENTA ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 3 | United States;Spain;Korea, Democratic People's Republic of;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan United States;Spain;Korea, Democratic People's Republic of;Turkey;Austria;Israel;Russian Federation; ... | ||
| 2 | EUCTR2012-001646-18-IT (EUCTR) | 08/04/2014 | 26/06/2013 | Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH) | A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentanin subjects with inop ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 16.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 16.0; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 3 | Spain;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of Spain;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina; ... | ||
| 3 | NCT01894022 (ClinicalTrials.gov) | January 23, 2014 | 3/7/2013 | A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentanin Subjec ... | An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentanin Su ... | Hypertension | Drug: Ambrisentan 5 mg | GlaxoSmithKline | NULL | Terminated | 18 Years | 80 Years | All | 19 | Phase 3 | United States;Argentina;Austria;Canada;China;Czechia;Germany;Israel;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Saudi Arabia;Spain;United Kingdom;Czech Republic United States;Argentina;Austria;Canada;China;Czechia;Germany;Israel;Japan;Korea, Republic of;Mexico; ... |
| 4 | EUCTR2012-001642-17-NL (EUCTR) | 16/12/2013 | 15/08/2013 | An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentanin su ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 16.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 16.0; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;Japan;China;Korea, Republic of Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina; ... | |||
| 5 | EUCTR2012-001646-18-NL (EUCTR) | 27/09/2013 | 15/08/2013 | Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH) | A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentanin subjects with inop ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 17.0; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Spain;Turkey;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;Japan;China;Korea, Republic of Spain;Turkey;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Mexico;Can ... | |||
| 6 | EUCTR2012-001646-18-CZ (EUCTR) | 18/09/2013 | 09/07/2013 | Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH) | A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentanin subjects with inop ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 17.0; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Arg ... | |||
| 7 | EUCTR2012-001642-17-CZ (EUCTR) | 18/09/2013 | 01/08/2013 | An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentanin su ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 14.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 14.1; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 3 | Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina; ... | ||
| 8 | EUCTR2012-001646-18-GB (EUCTR) | 02/09/2013 | 12/06/2013 | Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH) | A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentanin subjects with inop ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 17.0; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: Ambrisentan ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Arg ... | |||
| 9 | EUCTR2012-001642-17-GB (EUCTR) | 02/09/2013 | 12/06/2013 | An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentanin su ... | subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 14.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) MedDRA version: 14.1; ... | Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN Other descriptive name: ambrisentan Trade Name: Volibris Product Name: GSK1325760 Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN ... | GlaxoSmithKline Research & Developement Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina; ... | ||
| 10 | NCT01884675 (ClinicalTrials.gov) | September 2013 | 20/6/2013 | Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. | A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH). A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of AmbrisentanIn Subjects With Ino ... | Hypertension | Drug: Ambrisentan 5 mg;Drug: Placebo | GlaxoSmithKline | NULL | Terminated | 18 Years | 80 Years | All | 33 | Phase 3 | United States;Argentina;Austria;Canada;China;Czech Republic;Germany;Israel;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Saudi Arabia;Spain;United Kingdom United States;Argentina;Austria;Canada;China;Czech Republic;Germany;Israel;Japan;Korea, Republic of; ... |